EC
TERN

EntryPoint Capital’s Terns Pharmaceuticals TERN Stock Holding History

EntryPoint Capital’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,096
Closed -$206K – 915
2025
Q4 		$206K Buy
+5,096
New +$118K 0.08% 541
2025
Q2 		– Sell
-73,293
Closed -$202K – 815
2025
Q1 		$202K Buy
73,293
+12,905
+21% +$52.7K 0.09% 534
2024
Q4 		$335K Buy
+60,388
New +$409K 0.14% 305
2024
Q3 		– Sell
-9,069
Closed -$61.8K – 1119
2024
Q2 		$61.8K Sell
9,069
-4,301
-32% -$26.1K 0.09% 486
2024
Q1 		$87.7K Sell
13,370
-14,915
-53% -$97.4K 0.08% 496
2023
Q4 		$184K Buy
+28,285
New +$150K 0.18% 114

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

EntryPoint Capital's TERN Position: Q1 2026 in Review

EntryPoint Capital sold out of Terns Pharmaceuticals (TERN) in Q1 2026, closing a stake of 5,096 shares — an estimated $206K sold.

EntryPoint Capital first reported a position in TERN in Q4 2023 and held it in 6 quarters. The position peaked at $335K in Q4 2024. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • EntryPoint Capital reported no remaining Terns Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • EntryPoint Capital sold 5,096 Terns Pharmaceuticals shares in Q1 2026, an estimated $206K.
  • EntryPoint Capital first reported a position in Terns Pharmaceuticals in Q4 2023 and held it in 6 quarters.
  • EntryPoint Capital's Terns Pharmaceuticals position peaked at $335K in Q4 2024.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.